Bimatoprost ophthalmic solution 0.01% YSBP for glaucoma, open-angle

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Jun 2026: Trial started, NCT07661329
  2. 22 Jun 2026: Trial registered, NCT07661329

The trials

NCT07661329: A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

State
Under way
Phase
Phase 3
People
600 planned
Started
2 Jun 2026
Primary completion
1 Nov 2027
Arms
YSBP
Results
None posted
  1. 2 Jun 2026: Trial started
  2. 22 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.